51885-91-7 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 4-ethyl-3-iodo-benzoate is used as a key intermediate in the synthesis of DDR1 (Discoidin Domain Receptor 1) inhibitors. These inhibitors play a crucial role in the proliferation of cancer cells that exhibit high levels of DDR1, a receptor tyrosine kinase involved in cell adhesion, migration, and proliferation. By targeting DDR1, these inhibitors can potentially halt the growth of cancer cells and contribute to the development of novel cancer therapies.
Additionally, Methyl 4-ethyl-3-iodo-benzoate is utilized in the synthesis of GZD824, a compound that serves as an inhibitor for the treatment of chronic myelogenous leukemia (CML). CML is a type of blood cancer characterized by the overproduction of white blood cells, and GZD824 has shown promise in targeting the underlying molecular mechanisms of the disease, offering a potential therapeutic option for patients suffering from CML.
Check Digit Verification of cas no
The CAS Registry Mumber 51885-91-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,8,8 and 5 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 51885-91:
(7*5)+(6*1)+(5*8)+(4*8)+(3*5)+(2*9)+(1*1)=147
147 % 10 = 7
So 51885-91-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H11IO2/c1-3-7-4-5-8(6-9(7)11)10(12)13-2/h4-6H,3H2,1-2H3
51885-91-7Relevant articles and documents
Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl- N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2
Wang, Zhen,Zhang, Yali,Pinkas, Daniel M.,Fox, Alice E.,Luo, Jinfeng,Huang, Huocong,Cui, Shengyang,Xiang, Qiuping,Xu, Tingting,Xun, Qiuju,Zhu, Dongsheng,Tu, Zhengchao,Ren, Xiaomei,Brekken, Rolf A.,Bullock, Alex N.,Liang, Guang,Ding, Ke,Lu, Xiaoyun
, p. 7977 - 7990 (2018/09/06)
Discoidin-domain receptors 1 and 2 (DDR1 and DDR2) are new potential targets for anti-inflammatory-drug discovery. A series of heterocycloalkynylbenzimides were designed and optimized to coinhibit DDR1 and DDR2. One of the most promising compounds, 5n, ti